MicroRNA-24 overexpression modified the recurrence-free survival and overall survival of HCC patients.
Additionally, this microRNA overexpression modified the recurrence-free survival (relative hazard ratio [HR], 4.75; 95% confidence interval [CI], 2.66 8.47) and overall survival (HR = 3.58, 95% CI = 2.34 5.46) of HCC patients.
We need to modify the recurrence relation of the traditional Smith-Waterman approach to work on POGs.
We modify the recurrence score so that P d M ∝ C · ∑ G ∈ N P d G and the focality score so that P d (M) ∝ C.
Taking this into account, we redefine ei and en as ei = g| Gi | + | Li | and en = g| Gn | + | Ln |, (straight brackets denote the size of the respective set) and modify the recurrence under scenario (i) to en = ei1 + ei2 + g.
Considering the ESMO modified classification, the recurrence rates were 8.2% (8 out of 98), 23.1% (15 out of 65), 25.9% (15 out of 58), and 45.1% (28 out of 62) for intermediate risk/LVSI−, intermediate risk/LVSI+, high risk/LVSI−, and high risk/LVSI+, respectively (P<0.001).
When considering each subgroup of the ESMO modified classification, the recurrence rates were 7.0% (14 out of 198), 0% (0 out of 15), 8.2% (8 out of 98), 23.1% (15 out of 65), 25.9% (15 out of 58), and 45.1% (28 out of 62) for low risk/LVSI−, low risk/LVSI+, intermediate risk/LVSI−, intermediate risk/LVSI+, high risk/LVSI−, and high risk/LVSI+, respectively (P<0.001).
Additionally, this polymorphism also modified the overall survival and recurrence-free survival of osteosarcoma cases.
In addition, we modified the resection margin according to the location, tumor size, and recurrence status; therefore, it was difficult to discover factors related to recurrence on univariate analysis.
TNF-α inhibitors might impact the risk of cancer development, or modify the risk of recurrence of previous cancers [ 53].
The authors raise the intriguing possibility that the choice of hormone regimen may modify the risk for recurrence and account for some of the heterogeneity observed.
